Published in Food and Drug Law Weekly, June 24th, 2005
Results are compared to those cancer patients who received Neulasta in later chemotherapy cycles after developing a low white blood cell count. The study results were presented at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO).
The study showed a decrease of approximately 60% in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.